Coronavirus (COVID-19) Vaccine Update Click here to learn more.
For information about COVID-19 or to view additional resources, please click here.
The GW Medical Faculty Associates is proud of its physician scientists and their commitment to medical research. These clinical studies are designed to add to the medical knowledge base and relate to the treatment, diagnosis, and prevention of diseases or conditions.
Primary objective: To evaluate whether therapy with nivolumab following combined modality therapy (CMT) improves disease-free survival (DFS) compared with observation in patients with high risk anal carcinoma. Secondary objectives: 1a. To compare ...
Primary outcome measures: Pathologic complete response (pCR) rate assessed by independent central pathology review [Time Frame: Up to 12 weeks] Secondary outcome measures: Major pathologic response (mPR) rate assessed by independent central pathology ...
Primary objective: To evaluate whether the reconstruction complication rate at 24 months post radiation is non-inferior with hypofractionation. Secondary objectives: To evaluate the incidence of acute and late radiation complications, based on Common ...
Primary outcome measurements: Overall survival (OS) [Time Frame: Up to 2 years post treatment] Secondary outcome measurements: Instrumental Activities of Daily Living (IADL) [Time Frame: Up to 2 years post treatment] Inclusion Criteria: Newly ...
Primary objective: To compare the progression-free survival (PFS) of patients receiving high-dose cholecalciferol (vitamin D3) in combination with standard chemotherapy (leucovorin calcium, fluorouracil, and oxaliplatin [FOLFOX] or leucovorin ...
Primary objective: To assess the efficacy of concurrent definitive therapy followed by nivolumab compared with concurrent definitive therapy followed by observation in terms of progression-free survival (PFS). (Phase II) II. To assess the efficacy of ...
Primary objective: To compare overall survival in metastatic prostate cancer patients who are randomized to standard systemic therapy (SST) plus definitive treatment of the primary tumor versus standard systemic therapy alone. Secondary objectives: ...
Primary objective: To evaluate the overall survival of fruquintinib plus BSC compared to placebo plus BSC in subjects with refractory mCRC. Inclusion Criteria: Provide written informed consent; Age >=18 years; Histologically and/or cytologically ...
Main inclusion criteria: 1. Atopic Dermatitis with IGA ≥ 3 or use of biologics.
Main inclusion criteria: Individuals diagnosed with generalized PN, defined as the presence of ≥ 10 pruriginous nodules, involving at least 2 distinct anatomical areas: for example, either 2 limbs; or a single limb and some axial portion of the body. ...